Myeloablation for Lymphoma — Question Answered?
Mené sur 370 patients atteints d'un lymphome non hodkginien à risque élevé ou intermédiaire de récidive, cet essai évalue, du point de vue de la survie sans progression et de la survie globale, l'efficacité d'une greffe autologue de cellules souches en traitement de consolidation
The value of early myeloablative treatment of aggressive lymphoma in adults has been the subject of argument for many years. Before the addition of rituximab to the four-drug regimen known as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), a meta-analysis of randomized trials showed similar survival among patients undergoing up-front autologous stem-cell transplantation and those undergoing standard chemotherapy. At that time, outside clinical trials, high-dose chemotherapy with autologous stem-cell support was recommended only for patients with primary refractory or relapsed aggressive lymphoma. The widespread use of CHOP plus rituximab (R-CHOP) chemotherapy has considerably improved overall survival rates among patients with diffuse . . .
New England Journal of Medicine , éditorial, 2012